ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: Finally, angiopoietin-like protein 3 increases in parallel with the severity of liver histology in patients with MASLD,49 and angiopoietin-like protein 3 inhibition is associated with a beneficial effect on whole-body insulin resistance and hepatic steatosis in mice.50